Thryv Therapeutics is a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.
Thryv Therapeutics's investors include Fonds de solidarité FTQ, Lumira Ventures, CTI Life Sciences Fund, Alexandria Venture Investments, Investissement Quebec.
Thryv Therapeutics is headquartered in Laval, Canada.
Thryv Therapeutics is a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.
Thryv Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Thryv Therapeutics — Funding & Investors." VCBacked, September 17, 2025, https://www.vcbacked.co/company/thryv-therapeutics. Accessed August 6, 2026.
VCBacked. (2025). Thryv Therapeutics — Funding & Investors. Retrieved August 6, 2026, from https://www.vcbacked.co/company/thryv-therapeutics
{{cite web |title=Thryv Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/thryv-therapeutics |website=VCBacked |access-date=August 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated